Bacterial Antigen Ingredients TRIZ Cases

Adaptive current sensing tunes time constant and DCR gain to keep power converters stable as inductor properties shift with temperature and age.

An Msp porin tunnel driven by an electric field enables faster DNA sequencing with less sample and fewer preparation steps.

A dual-V-region antibody binds IL-4 and IL-13 in one therapy, balancing strong cytokine inhibition with safe dosing for IPF treatment.

Controlled serotype 6A polysaccharide sizing improves conjugate vaccine filterability while preserving strong immunogenicity.

A multiserotype conjugate composition uses carrier proteins to extend pneumococcal coverage while preserving strong immune responses in children and adults.

A Leuconostoc citreum strain composition helps treat intestinal damage from IBD, NASH, and chemotherapy by restoring barrier-related gene expression.

Disulfide-stabilized mutant OspA fragment heterodimers improve cross-serotype Lyme protection while reducing booster needs and autoimmune risk.

Controlled E. coli culture conditions stabilize lipidation profiles in vaccine proteins, supporting scalable production without losing biological activity.

Genetic toxin mutations remove catalytic and binding activity, creating non-toxic vaccine carriers with stronger, longer-lasting potency.

PRR ligand repertoires trigger innate signaling and chemokine production to improve CAR T-cell homing and persistence in solid tumors.

Multi-serotype GBS polysaccharide-protein conjugates improve vaccine stability, resuspension, and immune protection in vulnerable populations.

An angled stem and compressible reservoir enable one-hand oral vaccine delivery to animals with lower stress, safer handling, and minimal residual volume.

A multi-agent nasal spray combines rifamycin, fluticasone, oxymetazoline, and bacterial antigens to treat chronic rhinosinusitis locally.

Skin micro-perforation paired with an epicutaneous patch boosts vaccine antibody response while avoiding needle pain and reducing antigen dose.

Using Lactococcus lactis JCM5805 by ingestion, this case improves UV-damaged skin moisture and redness without prolonged-use side effects.

A mixed CRM197 and tetanus toxoid carrier strategy expands 21-serotype pneumococcal coverage while strengthening antibody responses.

Quaternary ammonium cellulose membranes plus SiO2 remove charged impurities from capsular polysaccharides with lower complexity and no toxic reagents.

An LPS-derived feed or drink additive boosts early-life poultry vaccination against coccidiosis, reducing symptoms, resistance pressure, and feed costs.

A fusion of fHbp v1, v2, and v3 broadens meningococcal strain coverage while lower OMV levels help reduce fever in infant co-administration.

Infused donor CD4+ T cells restore help for exhausted tumor-reactive CD8+ T cells while limiting graft-versus-host risk.

Early use of inactivated H. pylori or its lysate helps balance Th1/Th2 immunity and reduce progression of eczema and asthma.

Aprotic-solvent conjugation helps multivalent pneumococcal compositions broaden serotype coverage while maintaining protective immune response.

VM proteins from pathogenic Leptospira enable subunit vaccines and tumor-cell killing while avoiding whole-cell vaccine limits.

Separate PCV-2/Mhyo and live PRRS vaccines within 5 cm to avoid overlap, improve local antigen presence, and protect pigs with minimal side effects.

Selected Bordetella pertussis peptides presented on MHC Class II drive CD4+ T-cell responses for longer-lasting whooping cough protection.

Modified antisense adjuvants block IL-10 or IL-10RA RNA to relieve immune suppression and improve vaccine and therapeutic efficacy.

Purified bacterial strain compositions suppress IgE and Th2 responses to induce regulatory T cells and immune tolerance in food allergy.

A capped, poly(A)-tailed in-vitro transcript mRNA improves stability and protein expression while avoiding DNA-related genetic damage.

PEGylated polysaccharides help multivalent pneumococcal vaccines broaden serotype coverage while lowering carrier protein immunogenicity.

Structural mapping of serotype 23A enables recombinant saccharide conjugates that improve vaccine immunogenicity and scalable production.

Separate LNP populations deliver modified mRNAs to boost multi-polypeptide expression while limiting immunogenicity and improving stability.

PglS-mediated in vivo glycosylation of ComP fusion proteins improves conjugation of glucose-ended pneumococcal polysaccharides.

A disulfide-stabilized hybrid OspA fragment improves purification and drives specific immunity across multiple Borrelia serotypes.

Targeting moDCs with CDN, TNF, and CD64 antibody improves mucosal vaccine efficacy and supports long-term protection on lung surfaces.

Chemically modified C. difficile toxoids balance immunogenicity and toxicity to deliver sustained neutralizing protection across toxin variants.

CDN, TNF, and CD64 targeting direct moDC activation to improve mucosal vaccine efficacy and sustain lung antibody memory responses.

Combining ALT-803 with antibodies boosts NK and T-cell cytotoxicity against cancer and infections while helping limit autoimmune responses.

Multiple serotype-specific glycoconjugates broaden pneumococcal vaccine coverage beyond PREVNAR 13® while sustaining immune protection in infants and elderly.

A liquid LNP formulation stays stable at room temperature, avoiding cold-chain storage and reconstitution errors in nucleic acid therapy.

Nanoparticles replace classical adjuvants to enable one-shot Mycoplasma protection with fewer site effects and better PRRSV vaccine stability.

Egg yolk antibodies from immunized ostriches treat bacterial infections while remaining active in the gastrointestinal tract, even in candy form.

Restricting intracellular manganese in streptococcal vaccine bacteria promotes wild-type protein expression and broader serotype immunity.

Pre-inoculation temperature and kLa conditioning of sterile growth medium boosts Bordetella PT yield and biomass while shortening fermentation time.

Removing serum and albumin from fish vaccines helps prevent cross-stitch spinal deformities while preserving immunity against intracellular pathogens.

Using anthrax protective antigen as a CMG-2-targeting carrier improves dendritic cell antigen delivery and boosts T-cell activation.

RNA-encoded Mtb antigens trigger strong T- and B-cell responses, offering safer TB protection without live vaccine replication risks.

Novel B. afzelii antigens improve early Lyme serology by raising sensitivity and specificity beyond conventional antigen tests.

Broader pneumococcal serotype coverage is achieved with glycoconjugate compositions that limit antigenic interference and preserve immune responses.

A priming Env that engages germline B cells followed by glycosylated N276 Env elicits VRC01-like HIV-neutralizing antibodies.

Pulmonary delivery of live attenuated MTBVAC reprograms lung macrophages and Th2 responses to reverse established asthma while retaining TB protection.

Contiguously repeated Ehrlichia immunogenic sequences broaden antigen coverage for diagnosis and immune protection across infection stages.

JRFL-envelope HIV-1 vectors improve dendritic cell transduction to generate high-titer human antibodies with lower immunogenicity.

Respiration-protein polypeptides enable poultry vaccination that cuts Campylobacter jejuni colonization while improving delivery practicality.

A CpG plus aluminum adjuvant boosts recombinant Y. pestis antigens to deliver high antibody titers and seroprotective immunity in one dose.

Spray drying replaces chilled non-solvents and lab-scale FNP processing, forming controlled particles that preserve payload stability at room temperature.

This fusion protein combines flagellin with mutated IgG4 Fc to preserve TLR5 activation while limiting unwanted immune responses.

This case uses microbiota-derived epitope variants to trigger cross-reactive T cells and strengthen anti-tumoral immunity.

A vaccine combines non-replicating PCV2 immunogen with live attenuated PRRS virus via separate freeze-dried cakes reconstituted before intradermal injection.

Antigen-loaded autologous monocytes induce arteriogenesis via controlled inflammation, eliminating allogeneic rejection risks and disease transmission hazards.